"One of the clear demonstrations of the dishonesty and self-interest attending Ms. Gibson's conduct was the fact she and the company she controlled did not in fact make any donations to the organizations she had mentioned in her publicity statements until public questioning of her claims," Mortimer said in the Melbourne court.
MIAMI – Cancer treatments that attack tumors based on their individual genetic traits -- not their location in the body -- far outperform traditional methods, extending survival for twice as many patients, a study said Saturday. The precision medicine field of targeted therapy involves testing tumors for clues about their genetic mutations, and matching patients with new drugs designed to block cancer's growth on a molecular level. Targeted options for patients have risen dramatically in the last two decades -- and one-day tumor testing and cell-free DNA analysis may become the standard of care, said lead investigator Apostolia Tsimberidou, professor of investigational cancer therapeutics at MD Anderson Cancer Center in Texas. "I am optimistic that in the next few years we will dramatically improve the outcomes of patients with cancer with increasing implementation of precision medicine," she told reporters at the American Society of Clinical Oncology meeting in Chicago, the world's largest annual cancer conference. Tsimberidou and colleagues began studying the impact of these therapies in 2007, after seeing the success of Gleevec (imatinib) -- a breakthrough drug approved by U.S. regulators in 2001 that showed huge success against chronic myeloid leukemia.
In order for precision medicine to be successful, accurate characterization of the patient is necessary. A variety of biomarkers could provide the necessary data, collected through a variety of'omics techniques. Add to this the complication that biomarkers may differ between population groups, or indeed between individuals, and that tracking these biomarkers as the patient's status changes can be onerous, and the future of precision medicine could be described as bleak. Yet this pessimistic outlook has not stopped researchers from pushing forward in their search for accurate and robust biomarkers, which they hope will help to predict the risk of disease, ascertain the probability of positive clinical outcomes, and evaluate therapeutic efficacy. In this supplement to Science, these important topics are discussed, with a focus on advances in precision medicine research in China.
Cancer is entering a "new era" of personalised medicine with drugs targeted to the specific weaknesses in each patient's tumour, say doctors. Precision medicine is one of the big themes at the annual meeting of the American Society of Clinical Oncology. Doctors say "breath-taking" advances in the understanding of tumours are being used to unlock new treatments. But there are also concerns that patients are not getting access to the precision medicines we already have. The premise of precision medicine is that cancers are not all the same - even those in the same tissue - so a tailored approach is needed.